The role of the intestinal insulin receptor (IR) is not well understood. We therefore explored the effect of insulin (300 nmol/kg per day for 12 days) on the intestine in sex-matched C57Bl/6J mice. The intestinal and metabolic profiles were also characterized in male and female intestinal-epithelial IR knockout (IE-irKO) mice compared with all genetic controls on a chow diet or Western diet (WD) for 4 to 12 weeks. Insulin treatment did not affect intestinal size, intestinal resistance, or metabolic genes, but it reduced proximal-colon crypt depth and acutely increased colonic serine/threoninespecific protein kinase B (AKT) activation. Feeding with a WD increased body weight and fasting insulin level and decreased oral glucose tolerance in C57Bl/6J and IE-irKO mice. However, although the overall responses of the IE-irKO mice were not different from those of Villin-Cre (Vil-Cre):IR fl/+ and IR fl/fl controls, profound differences were found for female control Vil-Cre mice, which demonstrated reduced food intake, body weight, jejunal glucose transport, oral glucose tolerance, and fasting insulin and cholesterol levels. Vil-Cre mice also had smaller intestines compared with those of IE-irKO and IR fl/fl mice and greater insulin-mediated activation of jejunal IR and AKT. In summary, gain-and loss-of-function studies, with and without caloric overload, indicate that insulin did not exert remarkable effects on intestinal metabolic or morphologic phenotype except for a small effect on the colon. However, the transgenic control Vil-Cre mice displayed a distinct phenotype compared with other control and knockout animals, emphasizing the importance of thoroughly characterizing genetically modified mouse models. (Endocrinology 158: 2453(Endocrinology 158: -2469(Endocrinology 158: , 2017 A lthough the intestinal epithelium (IE) expresses high levels of the insulin receptor (IR), the functional role of insulin in the intestine remains largely uncharacterized. In metabolic tissues, insulin plays a key role in reducing blood glucose levels by stimulating a number of intracellular metabolic pathways, including cellular glucose uptake through the glucose transporter (GLUT) type 4 (1). Although the intestine does not express GLUT4, IE GLUT2 and the sodium-glucose2linked transporter 1 (SGLT1) facilitate luminal glucose transport to the circulation. Consistent with its essential role in glucose homeostasis, insulin inhibits the translocation of GLUT2 from the basolateral to the apical epithelial membrane, thereby delaying glucose uptake from the lumen of the small intestine (2). Furthermore, diet-induced hyperinsulinemia causes insulin resistance in the gut, which consequently increases glucose transport and hence blood glucose levels (3). Insulin is also known to modulate lipoprotein metabolism within the intestine. Hence, insulin suppresses the secretion of intestinal lipoproteins, whereas production of apolipoprotein (apo) B482containing chylomicrons by the small intestine is increased in insulin Abbreviations: AKT, serine/threonine-specific protein kinase B; apo, apolipoprotein; AUC, area under the curve; ELISA, enzyme-linked immunosorbent assay; FATP4, long-chain fatty acid transporter 4; FD4, dextran 4000 kDa-labeled fluorescein isothiocyanate; GLP-2, glucagonlike peptide
A lthough the intestinal epithelium (IE) expresses high levels of the insulin receptor (IR), the functional role of insulin in the intestine remains largely uncharacterized. In metabolic tissues, insulin plays a key role in reducing blood glucose levels by stimulating a number of intracellular metabolic pathways, including cellular glucose uptake through the glucose transporter (GLUT) type 4 (1) . Although the intestine does not express GLUT4, IE GLUT2 and the sodium-glucose2linked transporter 1 (SGLT1) facilitate luminal glucose transport to the circulation. Consistent with its essential role in glucose homeostasis, insulin inhibits the translocation of GLUT2 from the basolateral to the apical epithelial membrane, thereby delaying glucose uptake from the lumen of the small intestine (2) . Furthermore, diet-induced hyperinsulinemia causes insulin resistance in the gut, which consequently increases glucose transport and hence blood glucose levels (3) . Insulin is also known to modulate lipoprotein metabolism within the intestine. Hence, insulin suppresses the secretion of intestinal lipoproteins, whereas production of apolipoprotein (apo) B482containing chylomicrons by the small intestine is increased in insulin resistance (4, 5) . Insulin may therefore protect against dyslipidemia under physiological conditions (6) .
Although activation of serine/threonine-specific protein kinase B (AKT) by IR localized on the villus epithelium is thought to underlie the metabolic effects of insulin on the intestine (7), expression of the IR in crypt cells may modulate epithelial cell proliferation and differentiation via mitogen-activated protein kinase signaling (8) . Therefore, to determine the biological role of insulin in the intestine, a mouse model with constitutive deletion of the IR in the intestinal-epithelial IR knockout (IE-irKO) model was recently developed (9) . This transgenic mouse model was established by crossing IR fl/fl mice with animals expressing Villin-Cre (Vil-Cre)2recombinase which, within the small and large intestines, confers specificity to the villus and crypt epithelial cells. Phenotypically, these knockout (KO) mice have been reported to develop normally and, thus far, no data have demonstrated remarkable alterations in the intestinal morphology of the IE-irKO mice (9, 10) . However, when challenged with a high-fat diet, the KO mice are more resistant to metabolic disturbances, demonstrating improved oral glucose tolerance, reduced body weight gain, and lowered cholesterol and triglyceride levels (9, 10) . Notwithstanding, the studies reported to date are limited in their use of a single control group of animals, the IR fl/fl mice, and in some of the studies, only male animals were included (9) (10) (11) .
In contrast to previous reports on the IE-irKO mice (9-11), we have included both gain-and loss-of-function studies in order to examine the biological role of insulin and the IR in the intestinal tract. Intracellular signaling, receptor activation, and both ex vivo and in vivo intestinal permeability were also assessed, in addition to the metabolic and gut morphologic phenotype, in both female and male mice. Moreover, because previous studies used a 60% high-fat diet, the in vivo phenotype of these mice was analyzed under a high-fat, high-sucrose Western diet (WD) to more closely match common patterns of nutrient consumption. Finally, compared with previous reports of floxed controls alone (9-11), we compared mice without the intestinal IR (IE-irKO) with all of the mutated and transgenic control genotypes (i.e., Vil-Cre: IR fl/+ , IR fl/fl , and Vil-Cre) because of the reported ability of Cre recombinase to affect cell function (12, 13) .
Materials and Methods

Mice and diets
All mice were on a C57Bl/6J background and were purchased from The Jackson Laboratory (Bar Harbor, ME). Mice were housed at the University of Toronto, Toronto, Canada, or Novo Nordisk A/S, Copenhagen, Denmark. The animal studies were approved by the Novo Nordisk Ethical Review Council and the University of Toronto Animal Care Committee. Mice were 6 weeks old on arrival and either were fed normal rodent chow (study 1) or were allowed 1-week acclimatization before transfer to ad libitum rodent chow (Teklad rodent diet 2018; Envigo Inc., Huntingdon, UK) or a WD (D12079B; 41% calories from fat and 29% from sucrose; Research Diets Inc., New Brunswick, NY) for 4 or 12 weeks (studies 2 and 3).
Three main protocols were conducted, as described in the following paragraphs.
Study 1: Subcutaneous insulin, glucagonlike peptide 2, or vehicle in normal mice
Normal mice were treated with a high-dose of recombinant native human insulin, 300 nmol/kg (Novo Nordisk A/S, Copenhagen, Denmark), degradation-resistant human Gly 2 -glucagonlike peptide 2 [GLP-2; 0.1 mg/g -positive control (14) (15) (16) , American Peptide Company, Sunnyvale, CA]; or vehicle (Novo Nordisk) by subcutaneous injection once daily for 12 days. Twenty minutes before euthanasia, mice were given a final dosing. Mice were ;9 to 10 weeks old when euthanized, and each group included six male and six female mice.
Study 2: WD feeding time in normal mice
C57BL/6J mice were fed either WD or chow diet for 4 or 12 weeks before euthanasia. At each time point, 15 female and 15 male age-matched mice on each diet were studied. Progression in body weight was monitored during the experiment, and total fat mass was assessed by performing echo magnetic resonance imaging of the mice after 4 or 12 weeks on the diets. Furthermore, an oral glucose tolerance test (OGTT) was performed in subsets of the mice before euthanasia. Immediately after euthanasia, the intestine was dissected and length and mass were measured.
Study 3: IR KO in the intestinal epithelium and control mouse characterization
Mice with constitutive KO of IR in the intestinal epithelium were bred and genotyped by The Jackson Laboratory. Four genotypes were included (for more details, please see www.jax. org): homozygous (HOM) for the KO (Vil-Cre:IR fl/fl ; IE-irKO); heterozygous (HET) littermates (Vil-Cre:IR fl/+ ); parental mutated/loxP-floxed colony-mates (IR fl/fl ; B6.129S4(FVB)-Insrtm1Khn/J-backcrossed for 10 generations against C57Bl/ 6 but containing C57Bl6/J in addition to some C57Bl/6N based on limited SNP analysis by The Jackson Laboratory); and parental transgenic colony-mates (Vil-Cre; B6.SJL-Tg(Vil-Cre) 997Gum/J-backcrossed to C57Bl/6J 19 times). At the time of euthanasia, chow-fed mice were 8 to 11 weeks old, 4-week WD-fed mice were 10 to 11 weeks old, and 12-week WD-fed mice were 18 to 20 weeks old. Ten to 20 mice of mixed sexes were studied for each genotype. Some mice on a chow diet were given a high dose (300 nmol/kg) of sc insulin 20 minutes before euthanasia.
Body weight and food intake
In study 1, body weight was monitored approximately three times per week, and the treatment doses were adjusted accordingly. In studies 2 and 3, mice were weighed once per week. In study 3, the average food intake per cage of one to four mice was determined two to three times per week as the difference between the weight of the food on day 0 and the residual 2 to 3 days later, and the results were normalized per mouse per day.
OGTT
Mice were fasted for 6 hours before oral gavage of a glucose bolus (2 g/kg of body weight). Blood glucose level was measured with a portable glucometer (Glucometer OneTouch UltraEasy; LifeScan Inc., Burnaby, BC, Canada) over a 2-hour period (16, 17) .
Oral fat tolerance test
Mice were fasted overnight, and triolein [carboxyl- 14 C] (NEC674050UC; PerkinElmer, Inc., Waltham, MA) was administered by oral gavage at a concentration of 14.05 mCi/kg of body weight. The triolein stock solution was prepared by dissolving nitrogen-dried triolein in 20% Intralipid (I141; SigmaAldrich Co., Oakville, ON, Canada) and then mixing with deionized water to reach the final concentration (1.405 mCi/mL in 5% Intralipid). Blood samples were collected at 45 and 180 minutes, and plasma was extracted for counting (16, 17) .
Plasma insulin, cholesterol, and triglyceride
Plasma was collected after 6 hours of fasting for determination of insulin using the Ultra-Sensitive Mouse Insulin Enzyme-Linked Immunosorbent Assay (ELISA) Kit (Crystal Chem Inc., Downers Grove, IL). Nonfasted plasma cholesterol and triglyceride (TG) levels were measured using the Cholesterol Quantification (Sigma-Aldrich) and Triglyceride Colorimetric Assay (Cayman Inc., Ann Arbor, MI) kits, respectively.
Intestinal dissection and tissue collection
Mice were weighed, and the entire intestine was dissected and divided into the duodenum (proximal to the ligament of Treitz), jejunum plus ileum (remainder of the small intestine), cecum, and colon plus rectum (large intestine). The segments were flushed with ice-cold phosphate-buffered saline before weighing. For length measures, the distal end was mounted with a paper clip (3 g) to maintain constant tension. Fresh tissue was used for measurements of resistance and glucose transport. Intestinal sections (1 to 2 cm) and a liver sample (positive control) were frozen on dry ice and stored at 280°C for messenger RNA (mRNA) and protein analyses. Two-centimeter sections were fixed in 10% formalin overnight before paraffin embedding and sectioning for histologic and morphometric assessments (14) (15) (16) Real-time changes in voltage, current, and resistance were obtained by the Acquire & Analyze DAQ Software (Physiologic Instruments). Briefly, the electrodes were equilibrated in KRB for ;30 minutes before tissue mounting, and fluid resistance and voltage were offset. After mounting (three jejunal and three colonic pieces), the tissue was equilibrated for 20 minutes before initiation of the current clamp for 15 minutes. Tissue responsiveness was then measured by monitoring the increase in short-circuit current (Isc) in response to the addition of 100 mM of 3-isobutyl-1-methylxanthine (IBMX) and 10 mM of forskolin (Sigma-Aldrich) to the apical and basolateral chambers. Tissues that did not respond to IBMX/forskolin were discarded. The average tissue resistance of the jejunum and colon from each mouse was obtained on the basis of the three tissue replicates.
In study 3, glucose-mediated activation of Na + transporters in the apical membrane was determined according to the difference in short-circuit current (DIsc) when 10 mM of glucose was added to the apical chamber. The protocol was similar to that described previously, except that glucose was excluded from the KRB. Tissue was equilibrated for 20 minutes, but after 10 minutes, 10 mM of glucose was added to the basolateral chamber and 10 mM of mannitol was added to the apical chamber to maintain osmolality. After 20 minutes, tissue was voltage-clamped for 10 minutes, and 10 mM of glucose and 10 mM of mannitol were added to the apical and basolateral chambers, respectively. The change in Isc was monitored for 10 minutes, and DIsc was calculated as DIsc = Isc max 2 Isc basal and averaged over three tissue pieces per mouse. Tissue responsiveness at the end of the experiment was assessed with IBMX/forskolin as described previously.
In vivo permeability
Mice were fasted overnight before an oral gavage of 0.5 mg/g of body weight of dextran 4000 kDa-labeled fluorescein isothiocyanate (FD4) (Sigma-Aldrich). After a 90-minute gavage, blood was collected from the saphenous vein with EDTA-coated tubes (Sarstedt). The plasma was collected and measured at Ex/ Em 490/520 nm, and the concentration was determined from a premade standard curve (16) .
Gene expression analyses
Gene expression analysis was performed by quantitative realtime polymerase chain reaction (ViiA 7 RUO; Thermo Fisher Scientific, Mississauga, ON, Canada) on mucosa scraped from semithawed sections of distal duodenum, midjejunum, and distal colon. RNA was extracted using the RNeasy Plus Mini Kit (Qiagen, Toronto, ON, Canada) with a QIAshredder (Qiagen). Complementary DNA was prepared using RT Master Mix (NewLife BioChemEx, Bethesda, MD) and quantified using TaqMan Fast Advanced Master Mix (Thermo Fisher Scientific) with primers (Thermo Fisher Scientific) for
, and Tlr4 (Mm00445273_m1).
To normalize for variation in complementary DNA concentration, H3f3a (Mm01612808_g1) was amplified, and single-stranded DNA was quantified by the Quant-iT OliGreen ssDNA Assay kit (Thermo Fisher Scientific), as validated for gene expression analysis (18, 19) . Gene expression data were normalized to H3A by the DDCt method and to single-stranded DNA by 2^-Ct/ssDNA (ng/mL), and the effect of treatment was compared with that of vehicle-treated controls.
Protein activation analyses
In study 1, mice were injected with insulin/GLP-2/vehicle 20 minutes before euthanasia to measure activated AKT [pSer473] in jejunum, colon, and liver. Samples were collected ;4 cm distal from the midjejunum and from proximal-mid colon. Tissue was lysed in cell extraction buffer (Thermo Fisher Scientific) with added AEBSF (Calbiochem, Inc., Etobicoke, ON, Canada) and Protease Inhibitor Cocktail (Sigma-Aldrich) protease inhibitors, and was homogenized with 5-mm stainless steel beads (Qiagen) in the TissueLyser II (Qiagen) for 2 3 2 minutes at 30 Hz. Protein was determined using the BCA Protein Assay kit (Thermo Fisher Scientific). Activated AKT was measured with the AKT 
Histology and morphometric analysis
Villus and crypt height were measured on hematoxylin and eosin2stained cross-sections of jejunum and colon. Scores were obtained in a blinded-manner from two to four cross-sections per mouse. On average, 25 well-oriented crypts and villi were measured in the jejunum and 35 crypts in the colon per mouse, using Carl Zeiss Microscopy v4.8 software (Zeiss Canada, North York, ON, Canada) (14-16).
Immunofluorescence
IR expression in the duodenum, jejunum, and colon was assessed by immunofluorescence. Tissues were fixed by immersion in 10% neutral-buffered formalin overnight at 4°C then transferred to 70% ethanol and embedded in paraffin. Tissue sections (3 mm) were dewaxed in xylene and rehydrated using an ethanol gradient. Antigen retrieval was conducted by boiling in tris-ethylene glycol tetraacetic acid buffer, pH 9 (AMPQ17020; Ampliqon, Odense M, Denmark), followed by rinsing, blocking of endogenous peroxidase with 1% hydrogen peroxide, and treatment with an avidin/biotin blocking reagent (SP-2001; Vector Laboratories, Burlington, ON, Canada).
All of the following wash steps were performed with Trisbuffered saline (pH 7.4) (AMPQ40829; Ampliqon) with 0.05% Tween 20. The tissue sections were treated with a tyramide signal amplification blocking reagent (FP1020; PerkinElmer) and then incubated in primary antibody (2 mg/mL of mouseanti-InsR clone CT3, Catalog No. 05-1104; RRID: AB_1587206; Merck Millipore) for 45 minutes. After washing, the secondary antibody (1:200 of biotinylated donkey-anti-mouse; 715-065-151; RRID: AB_2340785; Jackson ImmunoResearch) was applied for 30 minutes followed by washing and incubation with peroxidaseconjugated Streptavidin (1:500; NEL704A001KT; PerkinElmer) for 15 minutes. Cy3-tyramide peroxidase substrate (1:100; NEL704A001KT; PerkinElmer) was then applied, followed by counterstaining with 4 0 ,6-diamidino-2-phenylindole (DAPI) and mounted in fluorescence mounting medium (S3023; Dako). The slides were scanned on an Olympus VS120 slide scanner using a 320 (NA 0.75, 0.33 mm/pixel) objective and a Cy3 filter set for the IR signal.
Statistics and analysis
Statistical analysis was performed with R Statistical Framework (3.1.3), and data were analyzed using a linear model by the lsmeans package (20) . In study 1, the treatment effect (insulin and GLP-2) was analyzed as the mean-fold difference to vehicle by transforming data to the natural logarithm, with body weight, sex, treatment, and interaction between treatment and sex as covariates. Statistical significance was found from the Dunnett (Dunnettx) post hoc analysis. In study 2, the effect of the WD was found by including the following covariates: initial body weight, sex, and diet. Finally, in study 3, the genotype effect on the independent variable was analyzed by including sex, initial body weight, genotype, and interaction between genotype and sex, followed by a Tukey post hoc test. In studies 2 and 3, the sex effect on the metabolic variables (end points) was generally statistically significant, and therefore female and male data were analyzed separately. In all three analyses, the assumption of variance homogeneity and normal distribution were checked according to plots of residuals and predicted values in q-q plots by the gvlma package (21) .
Area under the curve (AUC) for the OGTT and oral fat tolerance test data was calculated as the positive area under the curve and was determined with GraphPad Prism 6 (GraphPad Software, Inc., San Diego, CA). All data were expressed as adjusted mean (lsmeans) or mean-fold difference 6 95% confidence interval, and P , 0.05 was considered statistically significant.
Results
Study 1: Gain-of-function model
Body weight and OGTT were not affected by high-dose insulin
Because the dose of insulin selected for chronic administration was high (300 nmol/kg), we first determined the acute effects on blood glucose levels in freely feeding mice over a 5-hour period. Blood glucose declined after 1 hour but returned to normal levels after 5 hours [ Fig.  1(a) ], thereby confirming both the effectiveness of the insulin formulation and the absence of prolonged hypoglycemia. No differences in body weight were observed after 12 days of treatment with either insulin or GLP-2 [ Fig. 1(b) and 1(c) ] An OGTT that was performed on day 11 of treatment showed no difference in glucose tolerance in insulin-treated mice compared with controls [ Fig. 1(d) ]. Thus, despite the high plasma insulin level, the mice did not demonstrate an insulin-resistant glycemic phenotype.
High-dose insulin did not exert marked tropic effects on the small or large intestine
Insulin treatment for 12 days did not affect small intestinal mass or length (Table 1) . Similarly, insulin had no effect on the small intestine at the microscopic level, with no change in either jejunal villus height or crypt depth. In contrast, GLP-2 administration increased small intestinal mass by 32% compared with vehicle controls, in association with longer villi and deeper crypts (P , 0.01 to P , 0.001), as previously reported (14) (15) (16) . Interestingly, although insulin treatment had no effect on large intestinal weight or length, a small effect was found on the crypts in the proximal colon, which were reduced in depth by 8% compared with vehicle controls (P , 0.05). In the midpart of the colon, there was also a nonsignificant trend toward shortened crypts (by 9%; P = 0.08). These data suggest that high-dose insulin plays an inhibitory role in the growth of colonic crypts.
Acute insulin treatment increased phosphorylated AKT in the colon
The acute effect of insulin on the jejunum and colon was determined by examining phosphorylated AKT levels after 11 days of treatment with high-dose insulin Fig. 2(a) ]. Acute insulin administration in these animals significantly increased activation of AKT 20 minutes after dosing in the colon (twofold increase; P , 0.001); however, activated AKT was not detectable in the jejunum. Insulin also increased AKT levels in the liver (positive control) by ninefold (P , 0.001). Consistent with a greater effect of insulin on the colon, basal IR expression was significantly higher in the colon than in the small intestine (by 2.2-fold; P , 0.001) [ Fig. 2(b) ]. The jejunal IR mRNA was significantly lower than duodenal and colonic transcript levels; however, insulin treatment significantly increased IR expression in the jejunum (by 1.9-fold; P , 0.001), an effect that was not observed in the other regions of the intestine or for IGF-1R [ Fig. 2(c) ].
Small-and large-intestinal resistance was not altered by high-dose insulin treatment Barrier function of the jejunum and colon, as determined by measurements of tissue resistance, was not altered by 12 days of insulin treatment [ Fig. 2(d) ]. In contrast, chronic administration of GLP-2 significantly increased jejunal resistance (by 46%; P , 0.01), as expected (16) .
Small changes in jejunal gene expression patterns in insulin-treated male mice
To determine the effects of high-dose insulin treatment on intestinal metabolic capacity, the expression of several genes involved in glucose metabolism [SGLT1 (Slc5a1), GLUT2 (Slc5a2), sucrase (Sis), phosphoenolpyruvate carboxykinase 2 (Pck2), and glucose-6-phosphatase catalytic subunit (G6pc)] and lipid metabolism (longchain fatty acid transport protein 4 [(FATP4) Slc27a4], pyruvate dehydrogenase kinase isoform (PDK) 2 and 4, and ApoB48) was examined in the primary tissues responsible for nutrient absorption, the duodenal and jejunal mucosae, whereas genes related to intestinal barrier function [mucin-2 (Muc2), resistin-like molecule b (RELMb), and toll-like receptor 4 (TLR-4)] were examined in the colonic mucosa, which is highly exposed to the microbiota. These data are shown for males and females in combination [ Fig. 2(e) ], as well as separated by sex [ Fig. 2(f) ].
The jejunal mucosa of male mice only responded slightly to high-dose insulin by increasing the expression of Slc5a1 (by 2.2-fold; P , 0.05) as well as PDK2 (by twofold; P , 0.05), Slc27a4 (by 1.8-fold; P , 0.05), and ApoB48 (by 2.2-fold; P , 0.05). In contrast, in the colon, the expression of both Muc2 and TLR-4 was decreased by insulin treatment (by 0.7-fold and 0.6-fold, respectively; P , 0.05), although again, this was found only in male mice. No significant changes in expression patterns were found between insulin-and vehicle-treated mice for the remaining analyzed genes in males or for any of the genes in female mice.
Studies 2 and 3: Loss-of-function model
Loss of intestinal IR expression in IE-irKO mice
Immunofluorescence evaluation of the intestines from IE-irKO (HOM) mice demonstrated lack of IR expression in the duodenum, jejunum, and colon compared with expression in the Vil-Cre controls (wild-type) [ Fig.  3(a-c) ]. Villus height was significantly increased in jejunums from the HOM mice compared with the Vil-Cre animals, but not compared with jejunums from the other controls, HET and IR fl/fl mice [ (Fig. 3(d) ]. No changes in jejunal or colonic crypt depth were observed.
Intestinal structure and whole-body metabolism responded differentially to a WD in normal mice To establish the appropriate duration for feeding of the WD, C57Bl/6J control mice were fed either a chow diet or WD for 4 or 12 weeks, followed by assessment of changes in glucose homeostasis and intestinal size. Body weight was increased in both female and male mice after 12 weeks on the WD [ Fig. 4(a) ]. However, although both sexes demonstrated a twofold increase in fat mass after 4 weeks (P , 0.001), male mice showed a further twofold increase in fat mass after 12 weeks (P , 0.001) [Fig. 4(b) ]. After 12 weeks, WD-fed mice also displayed significantly impaired glucose tolerance in an OGTT, with the greatest change in male mice [ Fig. 4(c) and 4(d) ]. Fasted plasma insulin levels were also significantly increased after the 12-week WD compared with levels in chow-fed mice (by 2-and 2.5-fold in females and males, respectively; P , 0.01 to P , 0.001) [Fig. 4(e) ].
Finally, although a small increase in duodenal weight was noted in both diet groups (by 1.15-fold; P , 0.05), intestinal length and weight were otherwise reduced by the WD, with the greatest effects observed in the cecum and colon, where the mass was reduced by approximately 30% to 45% [ (Fig. 4(f) ]. Interestingly, this effect was similar in mice fed the 4-and 12-week WDs, suggesting that the reduction in intestinal mass is an early adaptation to the WD. Together, these data show that although intestinal alterations are apparent after a 4-week WD, a 12-week WD is required to induce a metabolic phenotype. Both feeding times were therefore included in the studies utilizing the IE-irKO mice.
Body weight of IE-irKO mice differed from that of Vil-Cre controls
Body weights were significantly different between the genotypes, both on a chow diet and after 4 and 12 weeks of a WD [ Fig. 5(a) ]. Hence, body weight gain was significantly reduced in the male HOM mice on a 4-week WD compared with results in the control animals, although this effect was lost by 12 weeks. Surprisingly, however, the most distinct and consistent differences in body weight were found in the Vil-Cre control mice, with lower weights in both chow-and WD-fed animals, mainly in the females (P , 0.05 to P , 0.01).
The accumulation of gonadal fat followed the trend of the body weight changes, although this did not reach significance between the genotypes [ Fig. 5(b) ]. The average food intake was also not different between the genotypes after the 4-week WD; however, after the 12-week WD, female Vil-Cre mice demonstrated significantly lower food intake compared with that of HET and IR fl/fl mice [ Fig. 5(c) ]. Thus, these data show a pronounced phenotype of the Vil-Cre mice compared with that of the other genotypes analyzed, including the IE-irKO animals.
Oral glucose tolerance in WD-fed IE-irKO mice differed from that of Vil-Cre controls After a 4-week WD, the HOM female mice exhibited markedly better oral glucose tolerance than that of the Vil-Cre mice (P , 0.05), but results were not different from those of other control animals [ Fig. 6(a) ]. This was also apparent following 12 weeks of WD (P , 0.01). Moreover, the female HOM and HET mice had significantly increased fasted insulin levels after the 4-week WD relative to levels in the Vil-Cre animals [ Fig. 6(b) ]. A similar difference in glucose tolerance was found in the male HOM and HET mice compared with the Vil-Cre mice at 4 weeks (P , 0.05), although this effect was lost by 12 weeks of the WD. There were no differences in fasting plasma insulin levels at 4 weeks, although levels were increased at 12 weeks in male HOM mice relative to levels in Vil-Cre animals [ Fig. 6(a) and 6(b) ]. Although changes in blood glucose levels can be caused by an impaired insulin response to glucose, they can also result from reduced glucose transport from the gut lumen to the circulation. Indeed, glucose-induced transporter activation in the small intestine, as assessed by Ussing Chamber technology, demonstrated a significant increase in the HOM mice compared with the Vil-Cre animals after 12 weeks of a WD [ Fig. 6(c) ]. These data therefore also indicate a Vil-Cre phenotype compared with the other control and IE-irKO animals.
Cholesterol but not lipid profiles were different in WD-fed IE-irKO mice and Vil-Cre mice
The absorption of triolein was independent of genetic background [ Fig. 7(a) ]. Rather, there were strong effects of both diet and sex. Hence, following the 4-and 12-week WDs, there was increased fat uptake in male compared with female mice (P , 0.001) [ Fig. 7(a) ], although plasma TG levels were not different [ Fig. 7(b) ]. Cholesterol levels were also elevated in the male mice (P , 0.001) and were significantly higher in female HOM and HET mice than in female Vil-Cre mice after 12 weeks of WD [ Fig. 7(c) ]. Therefore, main effects were due to the Vil-Cre phenotype rather than to the absence of IR.
Barrier function was not markedly altered in IE-irKO mice
Because proteins involved in the mucosal host-barrier function are reduced in male IE-irKO mice (22) , the physical host-barrier was examined using two approaches to determine barrier integrity. A small but significant increase in transepithelial resistance was found in the WD-fed colonic IE-irKO mucosa compared with the Vil-Cre mucosa (P = 0.03). However, no changes were found in jejunal transepithelial resistance for IE-irKO mice on either diet [ Fig. 7(d) ]. Similarly, in vivo permeability to oral FD4 did not demonstrate any marked changes in intestinal barrier function in response to either genotype or diet [ Fig. 7(e) ]. Plasma lipopolysaccharide levels were also not different between any of the groups of mice (data not shown).
Intestinal length and weight were different in IE-irKO mice compared with Vil-Cre mice
Intestinal size was affected by genetic background (Fig. 8) . Thus, intestinal length in IE-irKO mice was not different from that of control mice on either a chow diet or a 4-week WD, although the Vil-Cre mice demonstrated shorter total intestinal length after 12 weeks on a WD [ Fig. 8(a) ]. A similar conclusion was established by data on intestinal weight, except that duodenal weight after the 12-week WD was significantly reduced in HOM mice compared with that of both HET and IR fl/fl mice [ Fig.   8(b) ]. In contrast, the Vil-Cre animals demonstrated lighter small and large intestines under chow-fed conditions, consistent with their reduction in villus height [ Fig. 3(c) ]. Collectively, these data suggest that the presence or absence of the IR does not affect intestinal size, whereas the Vil-Cre transgenic background alone had a significant impact, which notably was still present when compensation for body weight differences were made in the statistical model (not shown).
Intestinal IGF-1R may compensate for lack of the IR in the intestinal epithelium
To determine whether activation of the IGF-1R compensates for the absence of the IR in the intestinal epithelium, phospho-AKT, -IR, and -IGF-1R levels in jejunum, colon, and liver (positive control) were determined. Of note, total IR expression was not different between the control groups for either the jejunal or colonic mucosa (data not shown). Unexpectedly, AKT [pSer473] levels in the jejunum and colon of mice treated acutely with high-dose insulin were not different between IE-irKO and control animals [ Fig. 9(a) ]. This effect in the KO mice was not caused by activation of the IR, which was significantly reduced in the intestines of these animals as expected. However, insulin-induced activation of the IGF-1R was found in the jejunum and colon of all mice, independent of genotype. Thus, although phosphorylated IGF-1R levels were not different in the IE-irKO intestinal mucosa compared with mucosa from the control animals, activation of this receptor by insulin could explain the downstream activation of AKT in IE-irKO mice. Feeding of a chow diet or WD for 12 weeks (in the absence of insulin treatment) was also associated with normal levels of activated AKT and the expected reduction in phosphorylated IR levels in the jejunum and colon of IE-irKO mice compared with levels in both genotype controls [ Fig. 9(b) and 9(c) ]. However, again, this AKT activation was associated with normal pIGF-1R levels [ Fig. 9 (b) and 9(c)]. Collectively, these findings suggest a potential compensatory regulation of the IGF-1R in mice lacking the IE IR.
Discussion
Despite the importance of insulin to metabolic homeostasis and high expression of the IR in the gut (23-28) , there is limited understanding of the effects of insulin on either the growth or function of the intestinal tract. Indeed, with the exception of small changes in glucose homeostasis, cholesterol levels, and IE cell apoptosis after radiation, relatively little functional difference between IE-irKO mice and their IR fl/fl controls was found in several recent reports (9) (10) (11) . The goal of the current study was to examine the biological role of insulin and the IR in the intestine by rigorously characterizing the intestinal and metabolic profiles of mice in well-controlled gain-of-function and loss-of-function studies, using both male and female mice as well as all appropriate genetic controls. The major findings of our study are that (1) high-dose insulin treatment for 12 days did not have profound tropic or metabolic effects on the small or large intestine; (2) constitutive deletion of the IR in the IE did not markedly change the metabolic or gut physiological phenotype of mice, either with or without caloric overload; and (3) transgenic Vil-Cre control mice alone and the female mice in particular demonstrated distinct metabolic and intestinal morphologic characteristics in association with alterations in intestinal function.
Although all regions of the intestine were found to express the IR, AKT was not activated by insulin in the jejunum. It is possible that this unexpected finding was due to high phosphatase activity in the small intestine or to changes in other factors that affect receptor kinetics. Nevertheless, the jejunal mucosa of male mice did respond to insulin treatment by increasing expression of the transcripts for the Na + /glucose transporter SGLT1 (Slc5a1), which mediates the uptake of ingested glucose from the small intestinal lumen. Although others have reported decreased oral glucose uptake in vivo in the IEirKO mice (9), we found no effect of IE-IR KO on jejunal glucose transport activity ex vivo (except in comparison with the Vil-Cre controls; see discussion below), and protein expression of total SGLT1 and Na + /K + ATPase, which provides the motive force for apical glucose transport, is not altered in the jejunum of mice lacking the IE IR (22) . However, insulin is known to affect the distribution of SGLT1 in enterocytes, increasing its localization in the apical side (29) . Conversely, it has been suggested that insulin interrupts the trafficking of GLUT2 between the basolateral and apical membranes, thereby inhibiting apical sugar absorption (2) , and that insulin enhances glucose transport despite decreasing Na + /K + ATPase expression (29) . The exact mechanism by which insulin supports or prevents apical and/or basolateral glucose uptake is, therefore, unclear. Nonetheless, neither chronic administration of insulin nor IE-IR KO was found to alter glucose homeostasis in vivo. Factors affecting glucose transport alone may therefore not be the sole driver for intestinal glucose absorption. Indeed, in healthy humans, insulin increases basolateral intestinal glucose uptake; this effect is not only lost in obese and diabetic individuals, but bariatric surgery also improves both intestinal insulin sensitivity and glucose uptake (30, 31) . Furthermore, we and others have found reduced expression of the incretin hormone, glucose-dependent insulinotropic hormone in IE-irKO mice (9, 10, 22) , which would be expected to impair glucose tolerance. The importance of the IE IR to the regulation of glucose homeostasis therefore remains unclear. In addition to enhancing SGLT1 (Slc5a1) expression, insulin treatment also increased FATP4 (Slc27a4) transcript levels. These findings are consistent with our observation that jejunal FATP4 protein levels are decreased in the absence of the IE IR (22) and with findings that FATP4 mediates insulin-induced fatty acid uptake by adipocytes (32) . However, circulating levels of TG were not altered by lack of the IE IR under normal dietary conditions [present study and (10)]. Furthermore, the role of FATP4 in dietary fat absorption remains controversial because although it can mediate enterocyte fatty acid uptake, it may not be essential for this function (33, 34) .
Similarly, although jejunal ApoA2, a component of high-density lipoprotein (HDL), and several colonic HDL-associated proteins are increased in IE-irKO mice fed a WD (22) , no changes in circulating levels of total cholesterol were observed in these animals; indeed, a small decrease in plasma cholesterol level was noted in the KO animals fed a 60% fat diet (10) . Together, these findings suggest a possible but small role for insulin in the production of HDL compared with that of other lipoproteins by the intestine.
Compared with the jejunum, the colon had twofold higher expression of the IR and demonstrated increased AKT activation in response to insulin. The colon houses the body's largest microbiome and therefore has a crucial role in maintaining barrier integrity and preserving the symbiotic relationship between the microbiota and the mammalian host. Indeed, high-dose insulin treatment was found to slightly decrease the mRNA expression of Muc2 and TLR-4, genes that are involved in regulating barrier integrity in the colon. Nonetheless, deletion of the IE IR reduces protein levels of MUC2 in the colonic mucosa (22) , suggesting an alternative effect of insulin in enhancing MUC2 secretion into the lumen. Whether any of these changes are mediated through an AKT-dependent pathway also remains unclear, as tumor necrosis factor-a has been reported to enhance Muc2 expression in a PI3K/AKT-dependent manner (35) . Furthermore, although these effects were observed in male mice, high-dose insulin for 12 days did not have any effect on ex vivo tissue resistance in either males or females (sex-separated data not shown), and loss of the IE IR does not alter the fecal microbiome in KO males (9). . Intracellular signaling pattern in IE-irKO mice after acute insulin treatment and after 12 weeks of a WD. M and F mice were administered (a) high-dose insulin 20 minutes before euthanasia or were fed either (b) a chow diet or (c) a WD for 12 weeks followed by determination of AKT, IR, and IGF-1R activation in jejunal and colonic mucosae, as well as liver (positive and negative controls for IR and IGF-1R, respectively). Data are presented as mean with 95% confidence interval. n = 4 to 10 mice for each genotype and treatment/diet group.*P , 0.05, **P , 0.01, and ***P , 0.001 as indicated. Alternatively, AKT activation in the colon was linked to increased proliferation of the crypt stem cells (36) , and loss of the IR in colonocytes increases radiation-induced apoptosis of these cells (11) . Because possible effects of insulin on other signaling pathways, such as Erk1/2 and canonical Wnt, were not interrogated in the current study, the mechanism by which chronic insulin treatment reduced colonic crypt depth in our normal mice and the significance of this finding remain unclear. Nonetheless, given that hyperinsulinemia may be associated with increased prevalence of colon cancer in humans (37, 38) , the results of the current study do not support a direct role for insulin in these effects.
Mice constitutively lacking the IE IR and fed a chow diet developed normally and did not display any remarkable alterations in body weight and metabolic or intestinal phenotype compared with those of heterozygous and IR fl/fl controls. Although these data are in accordance with previous reported findings using floxed mice alone as controls (9-11), they remain somewhat surprising given the high expression of IR in the intestine. We therefore examined the possibility that adaptive mechanisms are used in the IE-irKO mouse model, which would explain the unaltered phenotype. Our findings showed that insulin treatment not only induced AKT phosphorylation in the colon of KO mice, but it also activated the cognate IGF-1R, which is also expressed in the gut. However, because the effect was not genotype specific and basal IGF-1R activation was also not different between the genotypes, it is unclear whether IGF-1R activation compensated for the absence of the IR. Indeed, deletion of the IE IGF-1R does not compensate for loss of the IR in the colon with respect to radiationinduced apoptosis (11) . Furthermore, although several reports have indicated that constitutive IE-IGF-1R KO mice do not demonstrate any alterations in intestinal growth, fecal microbiome, or glucose homeostasis (9, 10), we previously demonstrated that inducible IE-IGF-1R KO mice lack normal intestinal growth responses to refeeding after a fast, as well as exhibiting impairments in GLP-22induced barrier function (15, 16 ). An alternative approach would therefore be the use of an inducible IE-irKO model to prevent any early adaption.
It is also possible that a third receptor subtype plays a role in the actions of insulin in the intestine, that being the hybrid heterodimer IR:IGF-1R, which is formed when IR and IGF-1R are coexpressed (38, 39) . Importantly, insulinlike growth factor-1 (IGF-1) demonstrates higher affinity than insulin for the hybrid receptor (40) . Furthermore, knockdown of the IR isoform A increases homodimerization of the IGF-1R in colon cancer cells, increasing the biological activity of IGF-1 (41). Thus, although IR:IGF-1R hybrids are presumably absent in the intestine of the IE-irKO mice, it cannot be discounted that some of the actions of IGF-1 are enhanced in this model.
In contrast to the chow-fed IE-irKO mice, animals lacking the IE IR and fed a WD demonstrated small but sexually dimorphic and temporal differences in body weight gain, food intake, and oral glucose tolerance compared with the IR fl/fl and HET control genotypes.
Furthermore, although no changes in oral fat handling were noted in either the male or female KO mice compared with controls, the male mice demonstrated genotypeindependent increases in fat absorption and plasma cholesterol levels compared with levels of the female animals. These findings emphasize the need for consideration of both male and female animals in studies of gut structure and function.
Intestinal morphology in normal mice fed a WD was also altered compared with that of chow-fed animals, with similar trends in the genetic models. Hence, the distal intestine was smaller in weight and length, changes that were obvious after only 4 weeks on a WD. It has recently been reported that compositionally defined rodent diets prepared from purified ingredients have an atrophic effect on the distal intestine and that the addition of soluble fibers, such as inulin, can prevent the obesogenic effect of diets containing a high-fat content and simple carbohydrates (42) . The compositional-defined WD diet used in the current study did not contain soluble fiber, suggesting that the rapid atrophic effect of the WD on the distal intestine was related to the absence of soluble fiber rather than to the enrichment in fat and sugar. These data also emphasize the need for matching the chow and fat-rich diets in studies of intestinal responses to diet changes.
Although insulin treatment did not alter jejunal or colonic transepithelial electrical resistance, a small increase in ex vivo barrier function was observed in KO mice fed a WD for 12 weeks. This did not translate to changes in permeability of the large-molecule FD4 in vivo, suggesting that insulin signaling may modulate colonic ion transport under conditions of diet-induced inflammation. How these effects are mediated remains unclear, as we have observed decreases in several solute carrier transport proteins as well as in cell membrane ATPases in the colon of WD-fed KO mice (22) . It also remains possible that imposition of more severe inflammatory stress on the gut, such as chemically induced enteritis or colitis, may allow better demonstration of alterations in barrier function in the IE-irKO mice. Consistent with this hypothesis, deletion of the IE IR increases the rate of colonic epithelial apoptosis after radiation (11).
Finally, an intriguing finding of the current study was the profound phenotype detected in the transgenic VilCre control mice. In particular, the female Vil-Cre animals displayed consistently lower body weight compared with that of IE-irKO mice under chow diets as well as 4-and 12-week WD feeding. The average food intake was also significantly lower in the female Vil-Cre mice, which could explain their lower body weight. However, when the mice were exposed to oral glucose, they were less glucose tolerant in comparison with other genotypes and especially IE-irKO animals. Reduced fasting insulin levels were also found after 4 weeks of a WD in the Vil-Cre females and after 12 weeks in the males. Conversely, the WD-fed Vil-Cre mice had reduced activity of the Na + / glucose transporter in the small intestine ex vivo, as well as reduced intestinal size and impaired colonic barrier integrity.
Consistent with the altered phenotype of these control animals, we also found that the jejunal proteome of male Vil-Cre mice differs from that of both the IE-irKO and IR fl/fl mice, and this is more marked under chow feeding than under a WD (22) . Although these findings are somewhat difficult to reconcile, they collectively indicate a reduced capacity for glucose handling and altered intestinal size and integrity in mice expressing Cre under the control of the Villin promoter. Because expression of this construct in the intestine has been reported to be exclusive to the epithelial cells (43) , it appears likely that Cre-induced changes in gut epithelial cell function are driving the observed phenotype. Consistent with this notion, Lee et al. (12) demonstrated that expression of Cre alone in the islet b-cell causes reduced glucose-stimulated insulin release, and interestingly, this phenotype is strongest in female mice. Conversely, expression of another Vil-Cre construct has been reported to improve glucose tolerance through increased expression of the bile acid receptor TGR5 and resultant enhancement of secretion of the incretin hormone GLP-1 (13) .
Furthermore, it cannot be completely discounted that a contribution to the phenotype of the C57Bl/6N genotype was introduced during the backcrossing of the IR-floxed Cre animals to the C57Bl/6 strain of mice, as described in the Methods. However, this seems unlikely because the most profound effects of Vil-Cre expression were found in comparison with the IE-irKO mice, whereas fewer differences were detected with the IR Nonetheless, the data clearly demonstrate that inclusion of Cre control mice in the study analysis is essential to appropriately assess the phenotype of interest.
In conclusion, despite significant proteomic changes in the intestinal mucosa of the KO mice (22) , neither high-dose insulin nor deletion of the IE IR exerted remarkable effects on intestinal morphologic and wholeanimal metabolic phenotypes. Importantly, there was no sign of enlarged intestinal size after high-dose insulin treatment, suggesting that the oral route of insulin administration may not lead to gross alterations in intestinal physiology and could offer a suitable alternative to insulin injection in patients with diabetes.
